Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - amlodipine besilate, quantity: 6.935 mg; perindopril arginine, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; colloidal anhydrous silica - apx-perindopril arginine/ amlodipine is indicated as substitution therapy for the treatment of hypertension and/or stable coronary heart disease in patients already controlled with separate doses of perindopril and amlodipine, given concurrently at the same dose level. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - buprenorphine hydrochloride, quantity: 0.216 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; mannitol; maize starch; povidone; magnesium stearate; citric acid; sodium citrate dihydrate - temgesic sublingual tablets are indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - reboxetine mesilate, quantity: 5.224 mg (equivalent: reboxetine, qty 4 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; crospovidone; magnesium stearate; silicon dioxide - indications: edronax is indicated for the treatment of major depression and is effective in preventing the relapse of depressive symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - codeine phosphate hemihydrate, quantity: 8 mg; aspirin, quantity: 300 mg - tablet, dispersible - excipient ingredients: citric acid; wheat starch; purified talc; saccharin sodium; calcium carbonate; disodium edetate; sodium lauryl sulfate - for the temporary relief of acute moderate pain, inflammation and fever

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; indigo carmine aluminium lake; lactose monohydrate; quinoline yellow; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: quinoline yellow; lactose monohydrate; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; iron oxide yellow; iron oxide red; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; stearic acid; microcrystalline cellulose; iron oxide red; hypromellose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - nortriptyline hydrochloride, quantity: 11.4 mg (equivalent: nortriptyline, qty 10 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - treatment of major depression